Zuellig Pharma has established a new strategic partnership with Lead Chemical to support the company as it ramps up international distribution of Loxoprofen patches around the region. A leading company in the analgesic patch segment, Lead Chemical was the first company to receive approval in Japan to manufacture and sell nonsteroidal anti-inflammatory analgesic patches that apply transdermal absorption technology. 

Under the new licensing agreement, Zuellig Pharma will help to commercialise Lead Chemical’s nonsteroidal anti-inflammatory analgesic patches most commonly used for pain relief and inflammation for selected markets across South East Asia and North Asia. 

Mr. Yoshiaki Mori, Representative Director, President of Lead Chemical shared, “We are pleased to partner with Zuellig Pharma. With their strong expertise and wide reach, we are confident that they are the right partner to help accelerate our growth in the region.” 

“Lead Chemical is one of the world’s leading pharmaceutical companies with a strong track record of developing innovative technologies to treat inflammation, pain and fever. By working with us, we hope to help Lead Chemical make their products available in various countries around the region,” said George Eassey, SVP Commercial Solutions.